Cybin Inc. (NYSE:CYBN - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Cybin in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will earn ($5.94) per share for the year. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Cybin's current full-year earnings is ($4.76) per share.
Separately, Guggenheim assumed coverage on Cybin in a research note on Thursday, March 13th. They set a "buy" rating and a $35.00 target price for the company.
Check Out Our Latest Analysis on Cybin
Cybin Stock Down 3.5%
Shares of Cybin stock traded down $0.30 on Wednesday, hitting $8.35. 461,522 shares of the company's stock traded hands, compared to its average volume of 265,756. The stock has a market cap of $191.30 million, a P/E ratio of -1.91 and a beta of 0.68. The firm's 50-day moving average is $7.24 and its 200 day moving average is $8.27. Cybin has a 52-week low of $4.81 and a 52-week high of $13.88.
Hedge Funds Weigh In On Cybin
Several large investors have recently added to or reduced their stakes in CYBN. Global Retirement Partners LLC bought a new position in Cybin during the fourth quarter worth $46,000. Cowa LLC bought a new position in Cybin during the fourth quarter worth $115,000. Essential Planning LLC. bought a new position in Cybin during the fourth quarter worth $138,000. Fore Capital LLC lifted its stake in Cybin by 70.6% during the fourth quarter. Fore Capital LLC now owns 31,421 shares of the company's stock worth $277,000 after purchasing an additional 13,000 shares during the last quarter. Finally, Diametric Capital LP bought a new position in Cybin during the fourth quarter worth $157,000. 17.94% of the stock is currently owned by institutional investors.
About Cybin
(
Get Free Report)
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.
See Also
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
